Cyclerion Therapeutics, Inc.

What they do

Cyclerion historically developed therapeutics for neuropsychiatric disorders, with a current focus on an individualized treatment for treatment-resistant depression (TRD) under a license from MIT. It also holds legacy soluble guanylate cyclase (sGC) stimulator assets it is seeking to monetize. Following a planned merger with Korsana Biosciences, the combined company will focus on Korsana's neurodegenerative disease programs.

Revenue drivers

• Legacy sGC stimulator assets — The company has no marketed products; revenue comes from occasional collaboration or licensing payments related to its legacy sGC platform. 2025 revenue was $2.1 million, down slightly from $2.0 million in 2024.
• None (pre-commercial) — Cyclerion is a development-stage biotech with no approved products. All revenue is non-product related, and the company has not disclosed any ongoing commercial agreements generating recurring revenue.

Recent performance

For fiscal 2025, Cyclerion reported revenue of $2.1 million, net loss of $3.5 million, and diluted EPS of -$1.11. Operating cash flow was -$3.3 million. Quarterly revenue was concentrated in Q4 2025 ($1.0 million) and Q3 2025 ($875,000), with no revenue in Q1 2026. As of June 30, 2026, cash and equivalents were $1.4 million, total assets $6.9 million, and shareholder equity $5.1 million.

Strategy

Management had prioritized CYC-126, an individualized therapy for TRD, and entered into a license agreement with MIT in September 2025 and a collaboration with Medsteer SAS in January 2026. However, due to cash limitations, they suspended advancing an integrated strategy for the TRD program. The company is now pursuing a merger with Korsana Biosciences, intending to make Korsana's neurodegenerative disease programs the primary business, while still seeking monetization of legacy sGC assets.

Risks

• Cash runway — With only $1.4 million in cash as of June 30, 2026, the company may not have sufficient funds to operate if the merger does not close as expected.
• Merger completion risk — The proposed merger with Korsana requires shareholder approvals and other closing conditions; failure to close would leave Cyclerion with limited strategic options.
• No approved products — Cyclerion has no marketed products, and its development pipeline (TRD program) is suspended due to cash constraints, limiting revenue potential.
• Shareholder dilution — The merger involves issuance of Cyclerion common stock to Korsana stockholders, which could significantly dilute existing shareholders' interests.

Outlook

Cyclerion anticipates the merger with Korsana to close in the third quarter of 2026, subject to conditions. After closing, the combined company will focus on Korsana's neurodegenerative disease pipeline. Meanwhile, the company continues to evaluate monetization opportunities for its legacy sGC assets. Given the cash position, the outlook is heavily dependent on successful merger completion.